A shortage of Sanofi’s Pompe disease therapies Lumizyme and Nexviazyme has lasted more than three months, and some U.S. patients are having infusions canceled, according to a Nov. 19 CNBC report.
Here are six things to know:
- Sanofi said shipping delays could interrupt infusions for some U.S. patients through the end of November. The company said it has made progress restoring supply in some countries.
- Sanofi attributes the shortage to manufacturing issues at its facility in Waterford, Ireland. The FDA inspected the plant in January and found violations involving two unrelated drugs, and June 22 it sent a warning letter saying the company still had not addressed the “underlying failure” to comply with manufacturing requirements. Sanofi said addressing the FDA’s concerns contributed to the supply disruption.
- Sanofi said there are no issues with drug quality and that it is prioritizing the most vulnerable patients. It advised patients to speak with a health professional before switching treatments because the medicines “are not interchangeable.”
- Sanofi’s latest supply update, from Oct. 16, said the company has shipped imported product to countries with treatment interruptions and that the European Medicines Agency and FDA have approved a new manufacturing process intended to expand production capacity. The update covers its enzyme replacement therapies for Pompe, ASMD, Fabry and Gaucher diseases.
- Patients typically receive Sanofi’s drugs by infusion every two weeks. Pompe disease affects about 1 in 19,000 babies, and patients lack an enzyme that breaks down a complex sugar, causing muscle weakness, breathing trouble and an enlarged heart. Patients and advocates told CNBC they fear missed infusions could cause irreversible declines.
- Some patients said Sanofi did not warn them about the supply risk. A Sanofi spokesperson told CNBC the company engaged patient advocacy groups, patients and clinicians as the disruption became clearer and is committed to transparent communication. The FDA said patient access is a priority and that it has offered assistance.